Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 16, 2010
Regenerative medicine promises cures
Author(s)Stephanie Sutton
Regenerative medicine has been described as holding the "promise of cures" by speakers at the first annual Translational Regenerative Medicine Forum, which was held last week in the US.
Advertisement
Regenerative medicine has been described as holding the "promise of cures" by speakers at the first annual Translational Regenerative Medicine Forum, which was held last week in the US.
A number of speakers gave their opinions and discussed recent progress, as well as the best practices and business models to bring new therapies to patients. Andrew von Eschenbach, Senior Director for strategic initiatives with the US Center for Health Transformation, explained that the promise of regenerative medicine demands a paradigm shift from treating disease to restoring health, while John Walker, Chairman of the biopharmaceutical company iPierian described regenerative medicine as the "medicine of the 21st century", according to a
"We are excited to bring together representatives from all facets of this emerging field to discuss the body's ability to heal itself through regenerative medicine technologies," DaLaura Kader, Vice President for strategic initiatives for the Regenerative Medicine Foundation, which sponsored the forum, said in the press statement.
The importance of regenerative medicine was also highlighted by Alan Lewis, president and CEO of the Juvenile Diabetes Research Foundation International, who said: "We have decided that regeneration is one of our top priorities." He also added that the organization has invested $60 million in recent years on research to regenerate islet cells in the pancreas that produce insulin.
The event also featured a first ever regenerative medicine venture forum where several regenerative medicine technologies were showcased to venture investors. "I was impressed with the opportunities out there from around the US," said P. Sherrill Neff of Quaker BioVentures. "I was pleased to see not only product companies, but infrastructure such as bioreactors and cryopreservation. That tells me we've got a real industry forming."
The Forum, sponsored by the Regenerative Medicine Foundation, is an annual event that aims to convene the regenerative medicine community to focus on fulfilling the promise of the field. In a
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement